Anticoagulation des patients diabétiques avec fibrillation auriculaire non valvulaire.

Administration, Oral; Anticoagulants/adverse effects; Atrial Fibrillation/complications/drug therapy; Diabetes Mellitus/drug therapy; Humans; Stroke/etiology/prevention & control; Warfarin/therapeutic use; Atrial fibrillation; Diabetes mellitus; Embolism; Haemorrhage; Anticoagulation

Abstract :

[en] Patients with diabetes have a higher risk of nonvalvular atrial fibrillation (NVAF), cerebral embolisms and anticoagulant-related intracranial bleeding when compared to nondiabetic patients. Non-vitamin K oral anticoagulants (NOACs) are progressively replacing antivitamin K agents among patients with NVAF. They are as efficacious as warfarin to reduce the risk of cerebral and systemic embolisms while reducing the risk of both severe and cerebral hemorrhages. Four studies reported results of prespecified subanalyses that compared results of efficacy and safety of NOACs (dabigatran, rivaroxaban, apixaban, edoxaban) in patients with and without diabetes, overall with similar results in both subgroups. ENGAGE AF-TIMI 48 is the only trial that reported a significant reduction of severe hemorrhages with edoxaban compared with warfarin in diabetic patients with NVAF.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

SPRYNGER, Muriel ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Angéiologie

Lancellotti, Patrizio ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie - Pathologie spéciale et réhabilitation

Language :

French

Title :

Anticoagulation des patients diabétiques avec fibrillation auriculaire non valvulaire.

Alternative titles :

[en] Anticoagulation of diabetic patients with nonvalvular atrial fibrillation

Publication date :

2021

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

93-97

Peer reviewed :

Peer reviewed

Available on ORBi :

since 02 September 2021

Statistics

Number of views

132 (1 by ULiège)

Number of downloads

190 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Huxley RR, Filion KB, Konety S, et al. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol 2011; 108: 56-62.
Stroke Risk in Atrial Fibrillation Working G. Independent predictors of stroke in patients with atrial fibrillation : a systematic review. Neurology 2007; 69:546-54.
Pegnyemb M, Lancellotti P. Mise à jour des recommandations de la Société Européenne de Cardiologie : au sujet de la fibrillation auriculaire. Rev Med Liege 2020; 75:706-10.
Peters P, Defraigne JO, Gothot A. Anticoagulants oraux : nouveaux horizons. Rev Med Liege 2012; 67: 37-44.
Sprynger M, Lancellotti P. Anticoagulants oraux directs. Avancée thérapeutique de la décennie. Rev Med Liege 2020; 75:310-5.
Saliba W, Barnett-Griness O, Gronich N, et al. Association of diabetes and glycated hemoglobin with the risk of intracerebral hemorrhage : a population-based cohort study. Diabetes Care 2019; 42:682-8.
Melon P, Garweg C, Lancellotti P, et al. Adhésion aux règles du traitement anti-thrombotique dans la fibrillation auriculaire. Rev Med Liege 2010; 65:299-303.
Scheen AJ. Rivaroxaban (Xarelto®) : nouvel anticoagulant oral, inhibiteur direct sélectif du facteur Xa. Rev Med Liege 2009; 64:538-43.
Lancellotti P, Scheen AJ. Dabigatran étexilate (Pradaxa®) : anticoagulant oral, inhibiteur direct sélectif de la thrombine. Rev Med Liege 2010; 65:588-92.
Scheen AJ, Lancellotti P. Edoxaban (Lixiana®) : nouvel anticoagulant oral pour le traitement et la prévention secondaire des maladies thromboemboliques Rev Med Liege 2016; 71:517-24.
Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation : executive summary. Eur Heart J 2017; 38:2137-49.
Van Mieghem W, Lancellotti P. CHADS2 risk score and rate of stroke or systemic embolism and major bleeding in patients with non-valvular atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants. Acta Cardiol 2017; 72:390-6.
Melon P, Lancellotti P. Recommandations Européennes 2010 pour le traitement anti-thrombotique de la fibrillation auriculaire : nouveaux scores pour l'évaluation des risques d'accident vasculaire cérébral et de saignement. Rev Med Liege 2010; 65:580-2.
Brambatti M, Darius H, Oldgren J, et al. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: results from the RE-LY trial. Int J Cardiol 2015; 196:127-31.
Bansilal S, Bloomgarden Z, Halperin JL, et al. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation : the Rivaroxaban once-daily, oral, direct factor Xa Inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF Trial). Am Heart J 2015; 170:675-82.
Ezekowitz JA, Lewis BS, Lopes RD, et al. Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban : results from the ARISTOTLE trial. Eur Heart J Cardiovasc Pharmacother 2015; 1:86-94.
Patti G, Di Gioia G, Cavallari I, et al. Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation : a study-level metaanalysis of phase III randomized trials. Diabetes Metab Res Rev 2017; 33:e2876.
Plitt A, Ruff CT, Goudev A, et al. Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial. Int J Cardiol 2020; 304:185-91.
Sprynger M. L'étude clinique du mois. Hokusai-VTE : edoxaban versus warfarine dans le traitement de la maladie thromboembolique veineuse symptomatique. Rev Med Liege 2013; 68:548-51.
Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369:2093-104.
Plitt A, Zelniker TA, Park JG, et al. Patients with diabetes mellitus and atrial fibrillation treated with NOACs: Meta-analysis of 8 outcomes in 58, 634 patients across 4 randomized controlled trials. Eur Heart J Cardiovasc Pharmacother 2020 Oct 16; pvaa120. doi: 10.1093/ehjcvp/pvaa120.